Transforming growth factor‐beta (TGF‐β) expression and interaction with proteinase 3 (PR3) in anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis
暂无分享,去创建一个
E. Csernok | M. Daha | J. Kekow | W. L. Gross | N. Mistry | C. Szymkowiak | Elena Csernok | W. Gross
[1] W. Gross,et al. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis , 1995, Current opinion in rheumatology.
[2] U. Helmchen,et al. Antineutrophil cytoplasmic autoantibodies, autoantigens, and systemic vasculitis , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[3] M. Cassatella. The production of cytokines by polymorphonuclear neutrophils. , 1995, Immunology today.
[4] W. Gross,et al. Determination of transforming growth factor beta 2 in human blood samples by ELISA. , 1995, JIM - Journal of Immunological Methods.
[5] W. Border,et al. Transforming Growth Factor β in Tissue Fibrosis , 1994 .
[6] M. Heller,et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. , 1994, Arthritis and rheumatism.
[7] P. Roux‐Lombard,et al. Elevated serum levels of TNF soluble receptors in patients with positive anti-neutrophil cytoplasmic antibodies. , 1994, British journal of rheumatology.
[8] M. Ernst,et al. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo , 1994, Clinical and experimental immunology.
[9] S. Wahl,et al. Transforming growth factor beta: a matter of life and death. , 1994, Journal of leukocyte biology.
[10] W. Gross. New developments in the treatment of systemic vasculitis. , 1994, Current opinion in rheumatology.
[11] M. Daha,et al. Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3 , 1993, European journal of immunology.
[12] W. L. Gross,et al. The clinical relevance of ANCA in vasculitis , 1993, Clinical and experimental immunology.
[13] W. Gross,et al. 'Classic' anti-neutrophil cytoplasmic autoantibodies (cANCA), 'Wegener's autoantigen' and their immunopathogenic role in Wegener's granulomatosis. , 1993, Journal of autoimmunity.
[14] T. Hada,et al. Local production and localization of transforming growth factor‐beta in tuberculous pleurisy , 1993, Clinical and experimental immunology.
[15] E. Csernok,et al. ANCA and associated diseases: immunodiagnostic and pathogenetic aspects , 1993, Clinical and experimental immunology.
[16] S. Wahl,et al. Reversal of acute and chronic synovial inflammation by anti- transforming growth factor beta , 1993, The Journal of experimental medicine.
[17] Stacey Schul tz-Cherry. Thrombospondin Causes Activation of Latent Transforming Growth Factor-Secreted by Endothelial Cells by a Novel Mechanism , 2002 .
[18] E. Ruoslahti,et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease , 1992, Nature.
[19] P. Kondaiah,et al. Autocrine induction of tumor protease production and invasion by a metallothionein‐regulated TGF‐beta 1 (Ser223, 225). , 1992, The EMBO journal.
[20] S. Wahl. Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure. , 1992, Journal of clinical immunology.
[21] J. Massagué,et al. Transforming growth factor-beta. , 1992, Cancer surveys.
[22] S. Wahl. The role of transforming growth factor-beta in inflammatory processes , 1991 .
[23] R. Winchurch,et al. Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF‐β , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[24] J. Kelley,et al. A rapid colorimetric bioassay for transforming growth factor beta (TGF-beta) using a microwell plate reader. , 1991, Journal of immunological methods.
[25] R. Goldschmeding,et al. Autoimmunity to lysosomal enzymes: new clues to vasculitis and glomerulonephritis? , 1991, Immunology today.
[26] D. Bainton,et al. Ultrastructural localization of proteinase 3, the target antigen of anti-cytoplasmic antibodies circulating in Wegener's granulomatosis. , 1990, The American journal of pathology.
[27] N. Shibata,et al. Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis , 1990, Clinical and experimental immunology.
[28] M. Sporn,et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 , 1990, Nature.
[29] M. Lotz,et al. Transforming growth factor-beta and cellular immune responses in synovial fluids. , 1990, Journal of immunology.
[30] H. Moses,et al. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin , 1990, The Journal of cell biology.
[31] H. Koeppen,et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[32] J. Lüdemann,et al. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme , 1990, The Journal of experimental medicine.
[33] S. Wahl,et al. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta , 1990, The Journal of experimental medicine.
[34] H. Moses,et al. Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium , 1988, The Journal of cell biology.
[35] C. Dinarello,et al. Basis for defective responses of rheumatoid arthritis synovial fluid lymphocytes to anti-CD3 (T3) antibodies. , 1986, The Journal of clinical investigation.
[36] M. Sporn,et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.